TG Therapeutics (TGTX) Aandelenoverzicht
TG Therapeutics, Inc. is een biofarmaceutisch bedrijf dat zich richt op de verwerving, ontwikkeling en commercialisering van nieuwe behandelingen voor B-cel gemedieerde ziekten in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 6/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
TGTX Community Fair Values
Create NarrativeSee what 132 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
TG Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$56.87 |
| 52 Week Hoogtepunt | US$59.30 |
| 52 Week Laag | US$26.76 |
| Bèta | 1.66 |
| 1 maand verandering | 10.02% |
| 3 maanden verandering | 6.86% |
| 1 Jaar Verandering | 75.69% |
| 3 jaar verandering | 522.21% |
| 5 jaar verandering | 76.83% |
| Verandering sinds IPO | 4,905.04% |
Recent nieuws en updates
Narratiefupdate • Sep 17
TGTX: High Efficacy B Cell Depletion And Subcutaneous Pathway Will Drive Re Rating
Analysts increased their fair value estimate for TG Therapeutics to $86 from $83, citing Street research that highlights strong Briumvi demand, evolving views on long term subcutaneous opportunities, and reaffirmed confidence that high efficacy IV therapies remain central in the B-cell depleting market despite new oral competitors. Analyst Commentary on TG Therapeutics Recent Street research on TG Therapeutics shows a wide range of views, but the most optimistic commentary focuses heavily on the growth runway for Briumvi and the potential of a future subcutaneous formulation.
Narratiefupdate • Sep 03
TGTX: High Efficacy Multiple Sclerosis Franchise Will Support Future Recovery
Analysts have raised their fair value estimate for TG Therapeutics from about $52 to roughly $70 per share, citing recent price target increases that highlight confidence in Briumvi’s position among high efficacy IV therapies, as well as the additional potential of a future subcutaneous version to expand the company’s market opportunity. Analyst Commentary Recent Street commentary on TG Therapeutics gives you a mix of optimism about Briumvi and its long term franchise potential, along with some clear areas of caution on execution, competition and valuation.
Narratiefupdate • Aug 17
TGTX: Subcutaneous Data Optimism Will Struggle Against Rising Execution Risks
Analysts have nudged their collective fair value estimate for TG Therapeutics higher, with the modelled price target rising from about $26.92 to $28.81 as they factor in updated views on Briumvi demand, potential revenue upside, and the longer term opportunity from a possible subcutaneous launch. Analyst Commentary Recent Street research on TG Therapeutics shows a split view.Recent updates
Narratiefupdate • Sep 17
TGTX: High Efficacy B Cell Depletion And Subcutaneous Pathway Will Drive Re Rating
Analysts increased their fair value estimate for TG Therapeutics to $86 from $83, citing Street research that highlights strong Briumvi demand, evolving views on long term subcutaneous opportunities, and reaffirmed confidence that high efficacy IV therapies remain central in the B-cell depleting market despite new oral competitors. Analyst Commentary on TG Therapeutics Recent Street research on TG Therapeutics shows a wide range of views, but the most optimistic commentary focuses heavily on the growth runway for Briumvi and the potential of a future subcutaneous formulation.Narratiefupdate • Sep 03
TGTX: High Efficacy Multiple Sclerosis Franchise Will Support Future Recovery
Analysts have raised their fair value estimate for TG Therapeutics from about $52 to roughly $70 per share, citing recent price target increases that highlight confidence in Briumvi’s position among high efficacy IV therapies, as well as the additional potential of a future subcutaneous version to expand the company’s market opportunity. Analyst Commentary Recent Street commentary on TG Therapeutics gives you a mix of optimism about Briumvi and its long term franchise potential, along with some clear areas of caution on execution, competition and valuation.Narratiefupdate • Aug 17
TGTX: Subcutaneous Data Optimism Will Struggle Against Rising Execution Risks
Analysts have nudged their collective fair value estimate for TG Therapeutics higher, with the modelled price target rising from about $26.92 to $28.81 as they factor in updated views on Briumvi demand, potential revenue upside, and the longer term opportunity from a possible subcutaneous launch. Analyst Commentary Recent Street research on TG Therapeutics shows a split view.Narratiefupdate • Aug 03
TGTX: Elevated Revenue Hurdles Will Restrain Returns Despite Subcutaneous Potential
Analysts have lifted their fair value estimate for TG Therapeutics stock from $20.00 to about $26.92, pointing to stronger Briumvi demand, potential quarterly revenue upside, and a future subcutaneous formulation that could widen the treatment's market and support longer term sales expectations. Analyst Commentary Recent Street commentary on TG Therapeutics highlights a wide spread in opinion on where the stock should trade, even as many analysts point to the same core driver, Briumvi.Narratiefupdate • Jul 20
TGTX: Elevated Briumvi Expectations And Subcutaneous Data Will Challenge Future Returns
The analyst price target for TG Therapeutics has moved from $17 to $20, as analysts cite updated assumptions for Briumvi. These include expectations around U.S. revenue versus guidance and a more supportive view on the subcutaneous opportunity reflected in their models.Narratiefupdate • Jul 06
TGTX: Subcutaneous Autoimmune Franchise Is Expected To Drive Future Re Rating
Analysts have raised their fair value estimate for TG Therapeutics to $83, up from $70. They cite updated models that reflect stronger assumptions for subcutaneous Briumvi following recent Phase 1 pharmacokinetic data.Narratiefupdate • Jun 22
TGTX: Fair Outlook As Late Stage Multiple Sclerosis Data Supports Recovery
Analysts have raised their price target for TG Therapeutics to $51.71 from $44.43, citing updated assumptions around profit margins, discount rate and future P/E that support a higher fair value estimate. What’s in the News for TG Therapeutics TG Therapeutics reported positive Phase 3 ENHANCE trial results showing a single 600 mg Day 1 infusion of BRIUMVI provided bioequivalent exposure to the existing two-step regimen, with safety and MRI outcomes consistent with prior studies, and plans a supplemental BLA filing in the second half of 2026.Analyse-artikel • Jun 17
TG Therapeutics (TGTX) Stock Looks 14% Overvalued as BRIUMVI Launch Hopes Face Off With Momentum
Recent Performance Snapshot for TG Therapeutics Stock TG Therapeutics (TGTX) has drawn fresh attention after a stretch of strong share price performance, with the stock up 0.5% in the latest session and gaining over the past week, month and past 3 months. At a last close of $50.54, TG Therapeutics now carries a market value of about $7.1 billion, supported by reported revenue of $700.349 million and net income of $461.896 million from its commercial stage biopharmaceutical operations. See our...Narratiefupdate • Jun 05
TGTX: Expanded Autoimmune Pipeline Will Support A Future Earnings Re Rating
Analysts have raised their fair value estimate for TG Therapeutics by $10 to $70, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels reflected in recent Street research. What's in the News TG Therapeutics reported Q1 2026 total global revenue of about US$205 million, with U.S. BRIUMVI net product revenue of roughly US$195 million and earnings per share of US$0.12 to US$0.17 versus Street expectations of US$0.28 to US$0.30.Narratiefupdate • May 21
TGTX: Execution Risks And Lower P/E Assumptions Will Pressure Future Upside
Narrative Update on TG Therapeutics The updated analyst price target for TG Therapeutics moves slightly lower to about $17.46 from roughly $17.57 as analysts adjust their assumptions on revenue growth, profit margins and future P/E, while still reflecting recent Street research that includes a $10 upward revision from H.C. Wainwright. Analyst Commentary Behind the modest adjustment in the average price target to about $17.46, bearish analysts remain focused on execution risks and how those could affect the valuation that investors are willing to pay for TG Therapeutics.Narratiefupdate • Apr 29
TGTX: JPMorgan Cut And Execution Risks Will Pressure Future Upside Potential
Analysts have modestly raised their fair value estimate for TG Therapeutics to about $17.57 per share, from roughly $17.32, citing refreshed assumptions around revenue growth, profit margins, discount rates and future P/E, as well as recent Street research including the latest JPMorgan price target update. Analyst Commentary Recent Street research, including a reduced price target at JPMorgan, points to a more cautious tone around TG Therapeutics, even as fair value estimates move only slightly.Seeking Alpha • Apr 19
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
Summary TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version’s trial is fully enrolled and could double the addressable market. Management guides conservatively for 2026 Briumvi U.S. net revenue of $825–$850 million and maintains disciplined operating expense targets. TGTX enhances financial flexibility with a $750 million term loan, expanded buybacks, and no equity dilution, supporting ongoing growth initiatives. Read the full article on Seeking AlphaNarratiefupdate • Apr 15
TGTX: Recent JPMorgan Cut Will Likely Expose Fragile Earnings Expectations
Analysts have adjusted their fair value estimate for TG Therapeutics from $15.49 to $17.32, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent price target revisions, including the $3 cut highlighted by JPMorgan. Analyst Commentary Recent commentary around TG Therapeutics has tilted cautious, with the $3 price target cut at JPMorgan reinforcing a more conservative stance on both execution and valuation risk.Narratiefupdate • Mar 31
TGTX: Shares Should Advance As Durable Multiple Sclerosis Data Supports Recovery
Narrative Update The blended analyst price target for TG Therapeutics is now effectively unchanged around $44, as recent moves, including a $3 trim at one firm and modest raises at others, reflect updated views on sector funding conditions, deal activity, and regulatory risk, while leaving core assumptions on growth, margins, and future P/E largely intact. Analyst Commentary Recent Street research around TG Therapeutics has been active but mixed, with one major firm trimming its target while others lift theirs, leaving the blended target roughly unchanged.Narratiefupdate • Mar 17
TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Drives Confidence
Analysts recently adjusted their price targets for TG Therapeutics in a mixed way, with one firm cutting its target by $3 while others raised theirs by $2 and $2. These changes reflect updated views on sector conditions, access to capital, M&A activity and company specific data catalysts.Narratiefupdate • Mar 03
TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Supports Upside
Analysts have nudged their price targets on TG Therapeutics in both directions recently, with moves such as a $3 trim at one firm and a $2 lift at another. These changes reflect updated views on discount rates, revenue growth assumptions, profit margins and future P/E, rather than a wholesale shift in the $44.43 fair value estimate used in this model.Narratiefupdate • Feb 17
TGTX: Shares Should Rebound As Revenue Outlook Supports Mixed Street Views
Analysts have made only a modest adjustment to their TG Therapeutics price targets, reflecting a slightly higher assumed discount rate and marginally lower future P/E expectations, while maintaining a consistent fair value estimate near $44 per share. Analyst Commentary Recent Street research on TG Therapeutics has been mixed, with some firms lifting price targets and others trimming them.Narratiefupdate • Feb 02
TGTX: Shares Should Rebound As Mixed Street Views Contrast With Strong Revenue Outlook
Analysts have adjusted their blended price target on TG Therapeutics slightly lower, trimming fair value by about $0.43 to reflect updated assumptions around growth, margins and future P/E following a mix of recent target revisions from major firms. Analyst Commentary Recent Street research on TG Therapeutics reflects a mix of optimism on the setup for biotech and specific caution around the company’s execution and valuation, which is feeding into the modest trim in the blended price target.Narratiefupdate • Jan 19
TGTX: Shares Should Rebound As Revenue Outlook Strengthens On Updated Guidance
Narrative Update Analysts have nudged their price target for TG Therapeutics higher to about $44.86, up from roughly $44.29. This reflects updated earnings models that incorporate slightly higher profit margin assumptions, a modestly adjusted discount rate and a small change to expected future P/E levels following recent Street research, including target increases from BofA, Goldman Sachs and JPMorgan.Narratiefupdate • Jan 05
TGTX: Higher JPMorgan Price View Will Likely Overstate Future Earnings Delivery
TG Therapeutics' analyst price target has moved higher, with a recent US$3 increase to US$49 as analysts refreshed their models after the latest earnings update. Analyst Commentary The latest move to a US$49 price target from JPMorgan signals that at least one major firm has refreshed its view following the recent earnings update, with a focus on updated assumptions in its valuation model.Narratiefupdate • Dec 22
TGTX: Higher Earnings Visibility Will Support A Re-Rating Over Time
Analysts have lifted their price target on TG Therapeutics shares, raising fair value by about $7 per share to $60, as updated post earnings models factor in a higher future P/E multiple despite slightly lower growth and margin assumptions. Analyst Commentary Following the latest earnings update, bullish analysts are increasingly highlighting TG Therapeutics as a beneficiary of improving fundamentals and greater earnings visibility, which they see as supporting a higher valuation range over the medium term.Narratiefupdate • Dec 08
TGTX: Shares Will Likely Rebound As Long Term Sales Milestone Approaches
Analysts have modestly raised their blended price target for TG Therapeutics, reflecting increased confidence in multi year Briumvi growth and updated post earnings models that point to a path toward more than $1 billion in annual sales. Analyst Commentary Recent Street updates reflect a predominantly constructive stance on TG Therapeutics, with upwardly revised price targets and reinforced positive ratings following the latest earnings update.Narratiefupdate • Nov 24
TGTX: Shares Will Likely Rebound Following Recent Buyback And Earnings Dip
Analysts have raised their price targets for TG Therapeutics, with recent updates reflecting increases of $3 to $49 and $2 to $55. This is based on confidence in ongoing sales growth and an improved margin outlook following the company's earnings report.Narratiefupdate • Nov 05
TGTX: Shares Will Likely See Renewed Momentum With Expanding U.S. Drug Adoption
Analysts have modestly increased their price target for TG Therapeutics, raising it from approximately $43.57 to $44.29. This adjustment is due to optimism about multi-year sales growth for Briumvi and updated post-earnings forecasts.Analyse-artikel • Oct 23
TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narratiefupdate • Oct 22
Analyst Commentary Drives Optimism for TG Therapeutics as Briumvi Growth Fuels Higher Price Targets
Narrative Update on TG Therapeutics Analysts have raised their price target for TG Therapeutics by $2 to $55. They cite expectations for sustained multi-year sales growth, supported by strong prospects for Briumvi in the U.S. market.Narratiefupdate • Oct 08
A Subcutaneous Launch Will Unlock The Anti-CD20 MS Market
Analysts have raised their price target for TG Therapeutics from $40.50 to $43.57, citing expectations of sustained Briumvi sales growth and an improved revenue outlook. Analyst Commentary Recent Street research highlights a range of perspectives regarding TG Therapeutics, with particular focus on Briumvi's market performance and growth trajectory.Analyse-artikel • Sep 30
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You
TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Mar 14
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Summary TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy. TG Therapeutics' strong cash position and ongoing Briumvi revenues are expected to fund operations and potential portfolio expansion, despite risks from trial data and international approvals. Read the full article on Seeking AlphaRendement voor aandeelhouders
| TGTX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 5.5% | 0.4% | -0.2% |
| 1Y | 75.7% | 36.4% | 11.9% |
Rendement versus industrie: TGTX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 36.4 % opleverde.
Rendement versus markt: TGTX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 11.9 %.
Prijsvolatiliteit
| TGTX volatility | |
|---|---|
| TGTX Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: TGTX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van TGTX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1993 | 399 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc. is een biofarmaceutisch bedrijf dat zich toelegt op de verwerving, ontwikkeling en commercialisering van nieuwe behandelingen voor B-cel gemedieerde ziekten in de Verenigde Staten en daarbuiten. Het bedrijf levert BRIUMVI, een anti-CD20 monoklonaal antilichaam voor de behandeling van volwassen patiënten met relapsing vormen van multiple sclerose (RMS), inclusief klinisch geïsoleerd syndroom, relapsing-remitting ziekte en actieve secundair progressieve ziekte bij volwassenen. De ontwikkelingspijplijn van het bedrijf omvat Ublituximab IV, een glycoengineer anti-CD20 mAb voor de behandeling van recidiverende MS; TG-1701 is een oraal beschikbare en covalent gebonden Bruton's tyrosinekinase (BTK) remmer die selectiviteit vertoont voor BTK in vitro kinase screening; en TG-1801, een bispecifiek CD47 en CD19 antilichaam.
TG Therapeutics, Inc. Samenvatting
| TGTX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$8.01b |
| Inkomsten(TTM) | US$441.49m |
| Inkomsten(TTM) | US$799.54m |
18.3x
Koers/Winstverhouding10.1x
P/S-verhoudingIs TGTX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TGTX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$799.54m |
| Kosten van inkomsten | US$140.94m |
| Brutowinst | US$658.60m |
| Overige uitgaven | US$217.11m |
| Inkomsten | US$441.49m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 3.11 |
| Brutomarge | 82.37% |
| Nettowinstmarge | 55.22% |
| Schuld/Eigen Vermogen Verhouding | 123.4% |
Hoe presteerde TGTX op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/18 11:48 |
| Aandelenkoers aan het einde van de dag | 2026/09/18 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
TG Therapeutics, Inc. wordt gevolgd door 18 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Alec Stranahan | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |